Zealand Pharma A/S is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. Established in 1998, the company has built significant exper... Zealand Pharma A/S is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. Established in 1998, the company has built significant expertise in engineering peptides to enhance biological activity, stability, and duration, enabling the development of next-generation therapeutics. Zealand Pharma focuses its research and development efforts on three primary therapeutic areas: obesity and obesity-related comorbidities, rare diseases, and chronic inflammation. The company's pipeline includes a diverse range of clinical and pre-clinical candidates, targeting conditions such as obesity, type 2 diabetes, congenital hyperinsulinism, short bowel syndrome, and various autoimmune and inflammatory disorders. Notably, Zealand Pharma has successfully brought peptide-based drugs to market, validating its platform and strengthening its industry presence. With a strong emphasis on addressing unmet medical needs, the company pursues global development and commercialization partnerships to expand access to its therapies. Zealand Pharma plays a notable role in advancing peptide research within the biotechnology sector, supporting innovation and the development of novel treatments for complex, underserved medical conditions.
Pending data availability
Waste Management Data missing for Zealand Pharma
We haven’t collected Waste Management data for Zealand Pharma yet, or the company
hasn’t made it publicly available.